OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
Le Li, Pei‐Sheng Wu, Xiumei Liang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 1043-1054
Closed Access | Times Cited: 18
Le Li, Pei‐Sheng Wu, Xiumei Liang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 1043-1054
Closed Access | Times Cited: 18
Showing 18 citing articles:
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Letter: Comparison of the Efficacy of Adjuvant PD ‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD ) Related HCC Versus Other Aetiologies
Jia‐Yong Su, Kang Chen, Zhen Liu, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Jia‐Yong Su, Kang Chen, Zhen Liu, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era
Jian‐Hong Zhong
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 806-810
Open Access | Times Cited: 6
Jian‐Hong Zhong
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 806-810
Open Access | Times Cited: 6
Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy
Xizhong Shen, Wei Yan, Erlei Zhang, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Xizhong Shen, Wei Yan, Erlei Zhang, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Adjuvant transarterial chemoembolization in resected macrotrabecular-massive hepatocellular carcinoma (ATAC-MACRO): a multicenter real-world retrospective study
Qingjun Li, Chang Xu, Jiaye Gu, et al.
Academic Radiology (2025)
Closed Access
Qingjun Li, Chang Xu, Jiaye Gu, et al.
Academic Radiology (2025)
Closed Access
Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions
Le Li, Zhenzhen Li, Li-Xin Pan, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 12, Iss. 5, pp. 525-533
Open Access | Times Cited: 3
Le Li, Zhenzhen Li, Li-Xin Pan, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 12, Iss. 5, pp. 525-533
Open Access | Times Cited: 3
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
Jingzhong Ouyang, Zhengzheng Wang, Kun Yuan, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1465-1477
Open Access | Times Cited: 7
Jingzhong Ouyang, Zhengzheng Wang, Kun Yuan, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1465-1477
Open Access | Times Cited: 7
Postoperative Lenvatinib plus PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with MVI (BCLC 0-A): A Propensity Score Matching Analysis
Awang Danzeng, Ling Guo, Zhenhua Yang, et al.
Journal of Gastrointestinal Surgery (2024) Vol. 28, Iss. 7, pp. 1104-1112
Open Access | Times Cited: 2
Awang Danzeng, Ling Guo, Zhenhua Yang, et al.
Journal of Gastrointestinal Surgery (2024) Vol. 28, Iss. 7, pp. 1104-1112
Open Access | Times Cited: 2
Recent advances in surgical management strategies for hepatocellular carcinoma
Zhen‐Bin Ding, Ying‐Hong Shi, Jiafeng Chen, et al.
hLife (2024) Vol. 2, Iss. 9, pp. 439-453
Open Access | Times Cited: 2
Zhen‐Bin Ding, Ying‐Hong Shi, Jiafeng Chen, et al.
hLife (2024) Vol. 2, Iss. 9, pp. 439-453
Open Access | Times Cited: 2
Systematic treatment in unresectable hepatocellular carcinoma: the most concerns
Jian‐Hong Zhong, Kang Chen, SU Ze, et al.
iLiver (2024) Vol. 3, Iss. 3, pp. 100112-100112
Open Access | Times Cited: 2
Jian‐Hong Zhong, Kang Chen, SU Ze, et al.
iLiver (2024) Vol. 3, Iss. 3, pp. 100112-100112
Open Access | Times Cited: 2
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.
Bernardo Stefanini, Giulia Francesca Manfredi, Antonio D’Alessio, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 647-660
Open Access | Times Cited: 2
Bernardo Stefanini, Giulia Francesca Manfredi, Antonio D’Alessio, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 647-660
Open Access | Times Cited: 2
Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
Haowen Tang, Wenwen Zhang, Junning Cao, et al.
BioScience Trends (2024) Vol. 18, Iss. 6, pp. 505-524
Open Access | Times Cited: 1
Haowen Tang, Wenwen Zhang, Junning Cao, et al.
BioScience Trends (2024) Vol. 18, Iss. 6, pp. 505-524
Open Access | Times Cited: 1
Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review
Jiahao Li, Yingnan Liu, Yuqi Qiu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Jiahao Li, Yingnan Liu, Yuqi Qiu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study
Yiman Li, X. Li, Xixi Xiao, et al.
European Radiology (2024)
Closed Access
Yiman Li, X. Li, Xixi Xiao, et al.
European Radiology (2024)
Closed Access
Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report
Jianrong Li, Da-Long Yang, Jinming Wang, et al.
Journal of Surgical Case Reports (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 1
Jianrong Li, Da-Long Yang, Jinming Wang, et al.
Journal of Surgical Case Reports (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 1
Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review
Lingbo Hu, Yenan Kong, Yingli Qiao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Lingbo Hu, Yenan Kong, Yingli Qiao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
A Novel Hybrid Model for Predicting Tertiary Lymphoid Structures in Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Yiman Li, X. Li, Xixi Xiao, et al.
(2024)
Closed Access
Yiman Li, X. Li, Xixi Xiao, et al.
(2024)
Closed Access
A commentary on ‘Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study’
Xin Zhao, Tianyang Mao, Qingyun Xie, et al.
International Journal of Surgery (2023)
Open Access
Xin Zhao, Tianyang Mao, Qingyun Xie, et al.
International Journal of Surgery (2023)
Open Access
